设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至zgyy8888@163.com

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:中国医师协会
总编辑:
杨秋

编辑部主任:吴翔宇

邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)

                  

过刊目录

2022 年第 6 期 第 17 卷

细胞周期蛋白依赖性激酶4/6抑制剂治疗激素受体阳性人表皮生长因子受体2阴性晚期乳腺癌的临床效果及安全性

Clinical effect and safety of cyclin-dependent kinase 4/6 inhibitors on the treatment of hormone receptor positive and human epidermal growth factor receptor-2 negative advanced breast cancer

作者:顾媛媛1张晓静1杨磊2关印1

英文作者:Gu Yuanyuan1 Zhang Xiaojing1 Yang Lei2 Guan Yin1

单位:1首都医科大学附属北京朝阳医院肿瘤科,北京100020;2首都医科大学附属北京朝阳医院医学研究中心,北京100020

英文单位:1Department of Oncology Beijing Chao-yang Hospital Capital Medical University Beijing 100020 China; 2Medical Research Center Beijing Chao-yang Hospital Capital Medical University Beijing 100020 China

关键词:乳腺癌;细胞周期蛋白依赖性激酶4/6抑制剂;不良反应

英文关键词:Breastcancer;Cyclin-dependentkinase4/6inhibitors;Adversereaction

  • 摘要:
  • 目的 探讨细胞周期蛋白依赖性激酶4/6CDK4/6)抑制剂治疗激素受体阳性(HR+/人表皮生长因子受体2HER-2)阴性晚期乳腺癌的临床效果及安全性。方法 回顾性收集201812月至20216月于首都医科大学附属北京朝阳医院接受CDK4/6抑制剂(哌柏西利或阿贝西利)联合内分泌治疗的57HR+/HER-2阴性晚期乳腺癌患者,采集患者临床病理及治疗信息,分析客观缓解率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)和不良反应。结果 纳入研究的57例患者接受CDK4/6抑制剂联合内分泌治疗后,疗效达完全缓解0例、部分缓解19例、稳定33例、进展5例,ORR33.3%19/57),DCR91.2%52/57),中位PFS15.2个月。治疗中患者的不良反应以血液系统毒性中白细胞减少[26.3%15/57)]、中性粒细胞减少[26.3%15/57)]最为常见。其他不良反应包括恶心、呕吐、腹痛、腹泻、肝功能异常、乏力、脱发、口腔炎等。结论 晚期HR+/HER-2阴性乳腺癌患者应用CDK4/6抑制剂联合内分泌治疗临床效果较好,不良反应可控,耐受性良好。

  • Objective To evaluate the clinical effect and safety of cyclin-dependent kinase 4/6(CDK4/6) inhibitors on the treatment of hormone receptor positive(HR+)/human epidermal growth factor receptor-2(HER-2) negative advanced breast cancer. Methods The clinicopathological and treatment information of 57 patients from December 2018 to June 2021, who received the treatment of CDK4/6 inhibitors(palbociclib or abemacicib) combined with endocrine therapy in Beijing Chao-yang Hospital, Capital Medical University were collected. The information was used to analyze the objective response rate(ORR), disease control rate(DCR), progression free survival(PFS) and adverse events of the treatment. Results   In the 57 patients, no complete remission was observed. The number of patients who reached the best efficacy of partial remission, stable, and progress were 19, 33 and 5, respectively. The ORR was 33.3%(19/57) and the DCR was 91.2%(52/57). The median PFS was 15.2 months. The most common adverse reactions were leucopenia26.3%(15/57) and neutropenia26.3%(15/57) in hematological toxicity. Other adverse reactions included nausea, vomiting, abdominal pain, diarrhea, abnormal liver function, fatigue, hair loss, stomatitis. Conclusion  In HR+/HER2- advanced breast cancer patients, CDK4/6 inhibitors combined with endocrine therapy has good clinical effect, controllable adverse reaction and good tolerance.

copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址:www.chinamedicinej.com 京ICP备2020043099号-3

当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。







安卓


苹果

关闭